Php80 - How Classification of Cell and Gene Therapies as Drugs, Devices or Procedures Could Have Significant Implications for Their Pricing and Reimbursement and Commercial Success

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.974
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2011English

Pcp37 - The Confidentiality Regarding Drugs Pricing and Reimbursement in Romania

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Barriers to Reimbursement Success for Non-Small Cell Lung Cancer Therapies in Australia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php140 - Current Challenges and Potential Solution for Pricing Regulatory and Reimbursement Framework of Innovative Drugs in Egypt

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Scientific Evaluation and Pricing of Medical Devices and Associated Procedures in France

Therapie
Pharmacology
2013English

The Pricing of Breakthrough Drugs: Theory and Policy Implications

PLoS ONE
Multidisciplinary
2014English

Behavior and Classification of NAT Devices and Implications for NAT Traversal

IEEE Network
Information SystemsComputer NetworksHardwareCommunicationsArchitectureSoftware
2008English

How Could Language Have Evolved?

PLoS Biology
ImmunologyMolecular BiologyGeneticsBiochemistryMicrobiology Biological SciencesAgriculturalNeuroscience
2014English

Php359 - Impact of Expedited Marketing Authorisation on Pricing and Reimbursement Outcomes for Drugs in the Us and Eu-5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy